Daily ECT for Treatment-Resistant Schizophrenia: A Promising Pilot Study
"Can intensive, daily electroconvulsive therapy (ECT) offer new hope for patients battling treatment-resistant schizophrenia? A pilot study reveals encouraging results."
Schizophrenia is a chronic and debilitating mental disorder affecting approximately 1% of the population worldwide. Sadly, a significant number of individuals diagnosed with schizophrenia, around 30%, do not respond to standard antipsychotic treatments. This condition is termed treatment-resistant schizophrenia (TRS), leaving patients with persistent symptoms and a diminished quality of life.
Electroconvulsive therapy (ECT) has emerged as a potential treatment option for TRS when medication proves ineffective. While previous studies have explored ECT for TRS, a novel approach involving daily intensive sessions remains largely unexamined. This approach aims to harness the potential benefits of frequent ECT administration.
This article delves into a pilot study that investigated the effectiveness of daily intensive ECT over eight consecutive days in reducing symptoms of schizophrenia among patients with TRS. It also examines the short-term and medium-term effects of this intervention, paving the way for potential advancements in TRS treatment.
Treatment Burden
Treatment-resistant schizophrenia can have substantial effects on symptoms, functioning, and quality of life. The available evidence suggests that treatment options may help some people, but outcomes vary and the impact of the illness remains significant. Any discussion of daily ECT should therefore distinguish promising pilot findings from established conclusions.
Existing Treatment Limits
Treatment-resistant schizophrenia is generally approached with established psychiatric treatments and ongoing clinical monitoring. When symptoms do not respond adequately, clinicians may consider additional interventions, including ECT, on an individualized basis. The limitations of current approaches mean that treatment decisions require careful attention to potential benefits, risks, and durability of response.
ECT’s Clinical History
ECT has been used in psychiatry for many decades and remains part of the treatment landscape for severe psychiatric disorders. Its role in schizophrenia has developed alongside research into efficacy, safety, and patient selection. The history of ECT therefore includes both important therapeutic use and continuing debate about its limitations.
Daily ECT: A Ray of Hope for Treatment-Resistant Schizophrenia?
The pilot study involved 14 patients diagnosed with TRS based on DSM-5 criteria. Participants underwent daily ECT sessions for eight consecutive days. Psychiatrists assessed the severity of the patients' disease, including positive and negative symptoms, psychopathology, and cognitive functions at baseline, at the end of the intervention, and at 4 and 12 weeks after completion.
- Symptom Reduction: Intensive daily ECT can significantly reduce psychiatric symptoms (positive and negative symptoms, psychopathology) in the short and medium term for individuals with TRS.
- Cognitive Impact: While initial cognitive decline is observed, cognitive functions tend to recover to baseline levels over time.
- Potential Booster Sessions: The increase in symptoms between 4 and 12 weeks following intervention suggests that booster sessions of ECT could be beneficial in sustaining the improvements.
Evidence From Reviews
A Cochrane review examined randomized controlled trials of ECT in people with treatment-resistant schizophrenia, using independently extracted data and risk ratios with 95% confidence intervals. Its 2019 conclusions reported moderate-quality evidence that ECT had a positive effect on medium-term clinical response compared with standard care. The New England Journal of Medicine likewise described ECT as an established treatment for severe mood and psychotic disorders, while a 2025 study noted continuing concerns about how durable ECT’s effects are in treatment-resistant schizophrenia.
Safety and Durability Concerns
ECT remains controversial in treatment-resistant schizophrenia despite evidence suggesting possible clinical benefit. The cited review highlights concerns about long-term side effects, particularly memory loss, and emphasizes the need to establish both clinical efficacy and safety. These concerns make it difficult to treat positive response in a pilot study as proof that ECT is appropriate or sustainable for every patient.
Contextualizing ECT
Comparisons between ECT and other treatments should account for both symptom response and the durability of benefit. A promising response to ECT does not by itself establish superiority over standard care or other established options. Because treatment-resistant schizophrenia is heterogeneous, comparative conclusions should remain cautious unless supported by direct, adequately designed studies.
Future Directions and Implications
While these results are encouraging, the study acknowledges the need for further research to solidify these findings. A key limitation of the pilot study is the absence of a control condition, which would help establish a stronger cause-and-effect relationship between daily ECT and symptom reduction.
A Comprehensive Treatment Model
The Lancet source emphasizes that comprehensive treatment is essential for people with schizophrenia, particularly the roughly one-third who do not respond adequately to first-line antipsychotic medications and are considered to have treatment-resistant schizophrenia. The Cochrane evidence base specifically addresses ECT for this population, reflecting the importance of evaluating it within broader treatment planning rather than in isolation. Together, these sources support viewing ECT as one possible component of care while recognizing the need for individualized clinical judgment.
Mechanisms to Test
Recent work proposes that ECT may improve refractory schizophrenia by increasing amygdala volumes and reducing posterior cerebellar connectivity. The accompanying report similarly identifies changes involving the amygdala and cerebellum as possible mechanisms. Randomized sham-controlled trials are needed to determine whether these neurobiological findings reliably explain clinical improvement.
Care Beyond One Intervention
Treatment-resistant schizophrenia presents challenges that extend beyond selecting a single procedure. Effective care may require sustained clinical follow-up, coordination among professionals, and attention to both benefits and adverse effects. The promise of daily ECT should therefore be considered within the practical realities of comprehensive, long-term treatment.
Individualized Decisions
For people living with treatment-resistant schizophrenia, treatment decisions involve more than measured symptom change. Potential benefits must be weighed against burdens, uncertainty, and concerns about adverse effects such as memory problems. Patient preferences, clinical circumstances, and ongoing monitoring are therefore important when considering an intensive intervention such as daily ECT.
Future studies should include larger sample sizes and control conditions, such as a sham ECT group or a standard ECT treatment group. Additionally, assessing cognitive performance using more specific and sensitive cognitive tests is warranted.
Despite these limitations, this pilot study provides a promising foundation for exploring intensive ECT regimens as a potential treatment option for individuals with TRS. It also highlights the need for continued research to optimize ECT protocols and identify strategies for sustaining long-term symptom control and improved quality of life for patients.